My first job in healthcare was in gastroenterology on 2 products Proton pump inhibitor and Prokinetic. So I’ve spend a lot of time with gastros, endoscopy doctors, many conferences and in many hospitals. The biggest indication market for both products was GERD (gastroesophagel reflux disease), which is considered very prevalent(10-20% of population). I remember clearly there were 2-3 key topics, one related to helycobacter eradication, and another one to refractory GERD. I can for sure tell that back in the days, EoE was never a topic, which makes me think- what is the true epidemiology of EoE, how many people really suffer from it, currently misdiagnosed with GERD. EoE prevalence in literature is considered 50/100000, rarer than some or rare diseases, just compare it with 10-20% for GERD… I Hope that in the nearest time, with more innovations coming for this field, more patient and hcp worldwide will know more about how to properly diagnose and treat this disease!
The New England Journal of Medicine (NEJM Group) has published positive Phase 3 results regarding our medicine in children aged 1 to 11 years with eosinophilic esophagitis (#EoE). Read more about how we are working with Regeneron to change the standard of care for young children living with the disease. Read our press release: http://spkl.io/604447BBQ